3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
31
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myeloid, Chronic-Phase
17
Leukemia
12
Breast Neoplasms
12
Prostatic Neoplasms
10
Neoplasm Metastasis
8
Recurrence
6
Pancreatic Neoplasms
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Carcinoma, Non-Small-Cell Lung
6
Melanoma
5
Lung Neoplasms
5
Leukemia, Myeloid, Acute
5
Philadelphia Chromosome
4
Multiple Myeloma
4
Lymphoma
4
Burkitt Lymphoma
4
Blast Crisis
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Ovarian Neoplasms
3
Glioma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycythemia Vera
2
Neuroblastoma
2
Leukemia, Myelomonocytic, Chronic
2
Interventions
bicalutamide
4
pembrolizumab
1
nilutamide
1
exemestane
1
darolutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bulbo-Spinal Atrophy, X-Linked
×
Dasatinib
×
Clear all
NCT00918385
2014-10-29
ARS
Duke University
Phase 2
Terminated
57 enrolled
8 charts